We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Imitation is the sincerest form of flattery, Basil. Excellent points made today in your posts about the effectiveness of Sareum with Dexamethasone, AZ, MSD and Eli Lilly and the undoubted value of Sareum moving forward. Keep them coming and if they get picked up by Twitter / social media then all the better. We are getting very close to substantive news now. Good luck to all Sareum shareholders, Brighty
The Sareum science in combination with Dexamethasone works.
The Sareum science in combination with AstraZeneca's WEE1 inhibitor adavosertib works.
The Sareum science in combination with Merck’s Keytruda works.
The Sareum science in combination with Eli Lillys Gemcitabine works.
In a nutshell our science is being proven to work time and time again and this surely equates to big news and big bucks soon.
Whoever it was that Tweeted this lifted my post from 9.39am today, above, word for word!
Basil, from March's research update RNS-
Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, notes that researchers from the Institute of Cancer Research (ICR) will present preclinical data on the combination of the Chk1 inhibitor SRA737 with AstraZeneca's WEE1 inhibitor, adavosertib, at the forthcoming American Association for Cancer Research (AACR) Annual Meeting.
SRA737 was discovered and initially developed by scientists at The ICR in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology, in a c.$300 million plus royalties licence deal, with Sareum eligible to receive 27.5% of all payments to CPF under the agreement.
The poster* describes how the combination of SRA737 and adavosertib potentiated cell death in cellular models of ovarian, breast and pancreatic cancer and in disease model studies of ovarian and breast cancer.
* "A study of combinatorial growth inhibition, cell death and DNA damage repair caused by CHK1 inhibitor SRA737 and WEE1 inhibitor adavosertib in TP53 mutated cell lines" (Abstract 1010), to be presented on-line during the "Cellular Responses to Anticancer Drugs" session on 10 April 2021. https://www.abstractsonline.com/pp8/#!/9325/presentation/2082
Sareum's CSO, Dr John Reader, commented: "We are encouraged to see yet another potential treatment modality for SRA737, in this case in tumours with a TP53 mutation, a mutation that is present in approximately half of all solid tumour cancers."
What excites me the most is whether it is Dexamethasone or not what we do know is that the Sareum science in combination with Dexamethasone works. The Sareum science in combination with AstraZeneca's WEE1 inhibitor adavosertib works. The Sareum science in combination with Merck’s Keytruda works. The Sareum science in combination with Eli Lillys Gemcitabine works. In a nutshell our science is being proven to work time and time again and this surely equates to big news and big bucks soon.
7p incoming and an 8p close today would set things up brilliantly for the projected news flow we are expecting. Don't forget Boil B's 20p by the end of June prediction - he's been pretty accurate so far with his predictions. FOMO Friday etc.
It is certainly one to watch with Sareum re our UKRI research as Dexamethasone – already prescribed for many conditions for its anti-inflammatory effects – was shown to reduce deaths by a third for Covid-19 patients on ventilators. It was revealed in March that one million lives had been saved globally by dexamethasone treatment re Covid. Now if you add the 2019 ground breaking successful research undertaken by Sareum with dexamethasone in to the UKRI mix this is pretty exciting.
I know that Thoth, Brighty and others have previously posted about Sareum and its 2019 successful trial with dexamethasone. Over the last few weeks I've been attempting to join the dots re our UKRI Covid research and what we are likely to hear from Sareum in the coming days. I'm wondering whether Sareum is combining its TYK2 with Dexamethasone on the UKRI research. The impact of such news would catapult our share price in to the stratosphere as it has been reported that Dexamethasone is proving to help halt Covid in its tracks. If we are indeed combining our Tyk2 with Dexamethasone this would be huge huge news.